+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 60Years
All Genders
ID07852091

Evaluating a New Combination Therapy of Immune Checkpoint Inhibitors and Interferon Alpha to Achieve Functional Cure in Chronic Hepatitis B Infection

Led by The Second Affiliated Hospital of Chongqing Medical University · Updated on 2026-10-01

1200

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Chronic Hepatitis B virus HBV infection poses a significant public health challenge, especially in China. This trial explores a new treatment approach aiming for a functional cure, defined as sustained loss of the Hepatitis B surface antigen HBsAg. Current therapies achieve this in less than 10% of patients, but prior research with sequential interferon alpha IFN therapy following nucleostide analogues NAs treatment showed improved rates up to 30-50% in some patients. This study builds upon those results by combining immune checkpoint inhibitors with IFN to potentially enhance immune control and increase cure rates.

CONDITIONS

Brief Title

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)

Research Team

D

Dachuan Cai, MD

M

Min Chen, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here